MTOR and neuroblastoma: Initial studies have identified synergistic combinations of ALK inhibitors with mTOR inhibitors [56] and with CDK4/6 inhibitors [57], and these combinations may serve to overcome some of the limitations of single-agent ALK inhibitor treatment for neuroblastoma.